Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Therapeutics (CTIC) -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (499)	3/3/2005 4:58:51 PM
From: gfp927z	Read Replies (1) \| Respond to of 946

Thanks Erik, eom.

To: Icebrg who wrote (499)	3/3/2005 5:47:08 PM
From: Clarksterh	Respond to of 946

GFP there appears to have been some confusion among Hambrecht's analysts. Stellar 3 recruited patients in the US, Canada, Western and Eastern Europe. South American patients were used in Stellar 4. Agree with Eric. This has been floating out there for quite a while and known to be wrong. If you want confirmation listen to the latest 2 cc's. In at least one of them I believe that he actually names the "three geographic regions" at play in ST 3 - western europe, eastern europe and NA. BTW - Something to think about - they recently talked about the fact that the rate of neuropathy in xyo arm was higher than pac arm until corrected for cycles. The ph ii results say that the rate of neuropathy in xyo is about 1/2 that of pac (a historical comparison), so to get more toxicity they must be getting substantially(!) more cycles. I'd guess greater than 50% more. AND we know that in ST 3 the patients getting more doses are surviving significantly longer. Ergo ... BTW2 - Sorry you got chased off the yahoo boards. You make a good (i.e. useful) critic. May I not suffer another PARS. Clark